Ascendis Pharma AS (NAS:ASND)
$ 151.26 -2.17 (-1.41%) Market Cap: 8.67 Bil Enterprise Value: 9.12 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

Q3 2019 Ascendis Pharma A/S Earnings Call Transcript

Nov 18, 2019 / 09:30PM GMT
Release Date Price: $106.98 (-4.92%)
Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Third Quarter 2019 Ascendis Pharma Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

Now I would like to hand the conference over to our Senior Vice President and Chief Financial Officer, Mr. Scott Smith.

Scott T. Smith;S;CFO
Ascendis Pharma A;Senior VP & Member of Executive Board

/- -

Thank you, operator. Thank you, everyone, for joining our third quarter 2019 financial results conference call today. I'm Scott Smith, Chief Financial Officer of Ascendis. Joining me on today's call is Jan Mikkelsen, President and Chief Executive Officer; Tom Larson, Chief Commercial Officer; Juha Punnonen, Head of Oncology; and Dr. Dana Pizzuti, Head of Development Operations.

Before we begin, I would like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot